A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

NCT05335941 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Metastatic Cancer

Interventions

DRUG: Pemetrexed
DRUG: Zimberelimab
DRUG: Etrumadenant

Sponsor

M.D. Anderson Cancer Center